Dr. Henrik B. Illum

Oncology | Hematology | Internal Medicine
1609 Hospital, 
Bedford, TX 
Offers Telehealth
27 Years of Experience
1609 Hospital, 
Bedford, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Henrik Illum is a Hematologist and an Oncologist in Bedford, Texas. Dr. Illum has been practicing medicine for over 27 years and is rated as an Experienced provider by MediFind in the treatment of Acute Mountain Sickness. His top areas of expertise are Pleuropulmonary Blastoma, Myelodysplastic Syndrome (MDS), Colorectal Cancer, and Diffuse Large B-Cell Lymphoma (DLBCL).

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Karolinska Institutet, 1999.0
Residency
Internal Medicine, Louisiana State University Health Science Center
Specialties
Oncology
Hematology
Internal Medicine
Licenses
Internal Medicine in TX
Board Certifications
American Board Of Internal Medicine
Fellowships
Hematology & Oncology, Louisiana State University HSC
Hematology/Oncology, Louisiana State University Health Science Center
Hospital Affiliations
Baylor Scott & White Medical Center Grapevine
Texas Health Harris Methodist Hurst-Euless-Bedford
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Texas Oncology, P.A.
1609 Hospital, Bedford, TX 76022

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drugs: N-803+Pembrolizumab, N-803+Carboplatin+Nab-paclitaxel+Pembrolizumab, N-803+Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed, Pembrolizumab, Carboplatin+Nab-paclitaxel or Paclitaxel+Pembrolizumab, Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: April 08, 2025
Intervention Type: Drug
Study Drugs: M7824, Pembrolizumab
Study Phase: Phase 3
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 31, 2024
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 3
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Bendamustine, Dacarbazine, Nivolumab
Study Phase: Phase 2
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Unknown
Publish Date: September 13, 2023
View 6 Less Clinical Trials

6 Total Publications

Dry-heat Depyrogenation Ovens for Pharmaceutical Compounding Facilities.
Dry-heat Depyrogenation Ovens for Pharmaceutical Compounding Facilities.
Journal: International journal of pharmaceutical compounding
Published: December 31, 2015
Similar Doctors
Advanced in Acute Mountain Sickness
Dr. Nicole S. Bartosh
Oncology | Hematology Oncology | Hematology
Advanced in Acute Mountain Sickness
Dr. Nicole S. Bartosh
Oncology | Hematology Oncology | Hematology

Oncology-Hematology Consultants PA

920 Santa Fe Dr, 
Weatherford, TX 
 (37.6 miles away)
817-596-0637
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Nicole Bartosh is an Oncologist and a Hematologist Oncology provider in Weatherford, Texas. Dr. Bartosh is rated as a Distinguished provider by MediFind in the treatment of Acute Mountain Sickness. Her top areas of expertise are Paget Disease of the Breast, Non-Hodgkin Lymphoma, Angiosarcoma, and Inflammatory Breast Cancer. Dr. Bartosh is currently accepting new patients.

Advanced in Acute Mountain Sickness
Dr. Jagathi D. Challagalla
Hematology Oncology | Oncology | Hematology
Advanced in Acute Mountain Sickness
Dr. Jagathi D. Challagalla
Hematology Oncology | Oncology | Hematology

Texas Oncology PA

10425 N Central Expy, 
Dallas, TX 
 (22.1 miles away)
214-361-2025
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jagathi Challagalla is a Hematologist Oncology specialist and an Oncologist in Dallas, Texas. Dr. Challagalla is rated as a Distinguished provider by MediFind in the treatment of Acute Mountain Sickness. Her top areas of expertise are Paget Disease of the Breast, Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, and Inflammatory Breast Cancer. Dr. Challagalla is currently accepting new patients.

Advanced in Acute Mountain Sickness
Dr. Sultan Chowdhary
Oncology
Advanced in Acute Mountain Sickness
Dr. Sultan Chowdhary
Oncology

Cancer Center Associates

2698 N Galloway Ave Ste 103, 
Mesquite, TX 
 (29.9 miles away)
972-686-6646
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sultan Chowdhary is an Oncologist in Mesquite, Texas. Dr. Chowdhary is rated as an Advanced provider by MediFind in the treatment of Acute Mountain Sickness. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Anemia, and Vitamin B12 Deficiency.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Illum's expertise for a condition
ConditionClose
      View All 11 Advanced Conditions
      View All 81 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile